GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunovant Inc (NAS:IMVTU) » Definitions » Dividends per Share

Immunovant (Immunovant) Dividends per Share : $0.00 (TTM As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Immunovant Dividends per Share?

Immunovant's dividends per share for the three months ended in Dec. 2023 was $0.00. Its dividends per share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00. Its Dividend Payout Ratio for the three months ended in Dec. 2023 was 0.00. As of today, Immunovant's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.


Immunovant Dividends per Share Historical Data

The historical data trend for Immunovant's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunovant Dividends per Share Chart

Immunovant Annual Data
Trend Dec18 Mar20 Mar21 Mar22 Mar23
Dividends per Share
- - - - -

Immunovant Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Dividends per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Immunovant's Dividends per Share

For the Biotechnology subindustry, Immunovant's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunovant's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunovant's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Immunovant's Dividend Yield % falls into.



Immunovant Dividends per Share Calculation

Dividends paid to per common share.


Immunovant  (NAS:IMVTU) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Immunovant's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Dec. 2023 )/ EPS without NRI (Q: Dec. 2023 )
=0/ 0
=N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Immunovant Dividends per Share Related Terms

Thank you for viewing the detailed overview of Immunovant's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunovant (Immunovant) Business Description

Traded in Other Exchanges
Address
320 West 37th Street, 6th Floor, New York, NY, USA, 10018
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).
Executives
Roivant Sciences Ltd. 10 percent owner CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Julia G. Butchko officer: Chief Dev. & Tech. Officer 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Michael James Elliott officer: Chief Scientific Officer 320 WEST 37TH STREET, NEW YORK NY 10018
George V Migausky director C/O DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Frank Torti director 2855 SAND HILL ROAD, MENLO PARK CA 94025
Peter Salzmann director, officer: Chief Executive Officer 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
W Bradford Middlekauff officer: General Counsel 200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922
Douglas J. Hughes director C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Atul Pande director C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Andrew J. Fromkin director C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FL, CAMBRIDGE MA 02139
Pamela Ann Connealy officer: Chief Financial Officer 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Eric Venker director C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
Myrtle S Potter director 10 FINDERNE AVE, BRIDGEWATER NJ 08807
Robert K Zeldin officer: Chief Medical Officer C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Health Sciences Holdings, Llc 10 percent owner 412 WEST 15TH STREET, FLOOR 9, NEW YORK NY 10011